-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Ascendis Pharma, Raises Price Target to $322

Benzinga·01/09/2026 14:25:30
Listen to the news
Wells Fargo analyst Derek Archila maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and raises the price target from $297 to $322.